CSF3 and acute myeloid leukemia: Additionally, a previous study investigated the efficacy of decitabine plus intermediate dose cytarabine combined with HLA-mismatched G-CSF-mobilized peripheral blood stem cells infusion (D-GPBSCs regimen) in 23 AML patients aged ≥ 60 years old in CR1.